Pricing wars for new Hepatitis C drugs have begun with AbbVie and Gilead Sciences dealing discounts and entering exclusionary deals. How far will these deals go and will they reach to other disease categories? More information available here. (Source: Robert Langreth, Bloomberg, 1/9/15)
You are here: / / Biotech’s Price Wars – Will They Cover More Than Just Hepatitis C?